Amanta Healthcare is a manufacturer of sterile liquid pharmaceuticals, centered on two-port IV fluid containers (SteriPort) and small volume parenterals (SVP) such as inhalation and ophthalmic solutions. SteriPort provides roughly 44% of revenue, while SVP adds about 20% from export markets, with the remaining balance from contract manufacturing. The competitive niche for special-feature plastic containers includes only a few global players like Otsuka and Fresenius Kabi, and Amanta claims to be the only Indian company exporting these BFS containers to Australia and Canada for three years. The business currently generates an EBITDA margin around 22% in Q1 FY27, but management expects this to expand to 25-26% by FY28 as new capacity and solar savings kick in, reflecting both a differentiated product and pricing discipline.
The durability of these economics is anchored in regulatory and technical barriers. SteriPort uses random copolymer polypropylene that withstands 125°C sterilization, while competitors' polyethylene degrades beyond 109°C, and drug compatibility studies show anti-cancer drugs begin to degrade in polyethylene within 90 minutes but in SteriPort after 28 to 45 hours. The company has sold over 30 crore bottles without a single fungal contamination complaint, and its dedicated two-port production lines contrast with competitors who run two-port and legacy products on the same line. NPPA classification for special bottles permits same pricing, and the company raised prices by INR2 per unit without market resistance, demonstrating pricing power. These factors create a sustainable niche despite large MNC competition, though Amanta's share in the two-port IV system market is around 30-35%.
The inflection comes from the SteriPort Line 3 expansion, lifting capacity from 6.6 crore to 12 crore bottles per year. After a 4-5 month delay, commercial production is targeted for late August 2026, with FDA inspection scheduled on 21 August. This line is expected to generate peak annualized revenue of INR120 crores within 12 months. Concurrently, the 10.8 MW captive solar plant was commissioned in June 2026, saving INR75 lakh per month, or roughly INR9 crores annually. The SVP facility, with a total capex of INR40 crores, is slated to be operational in March 2027, focusing on high-margin inhalation and preservative-free ophthalmic products. By FY28, the company targets revenue of approximately INR425 crores with an EBITDA margin of 25-26%, implying EBITDA around INR116 crores, up from FY27's projected revenue of INR370 crores (excluding SVP contribution).
Management has shown a pattern of transparently adjusting timelines. In February 2026, they guided SteriPort commercialization for April 2026, which slipped to August 2026 due to civil construction, and they communicated this slippage on the May 2026 call. They have delivered on debt reduction, improving debt-to-equity from 3x to about 1x over three years, and have repaid INR36 crores in the current year. Solar commissioning was completed on schedule in June 2026. The FY27 revenue guidance was trimmed from roughly INR400 crores (February) to INR370 crores (August) because of the SteriPort delay, but the FY28 target of INR425 crores remains intact. Capital allocation is disciplined, with capex funded through IPO proceeds and internal accruals, and a further INR30-40 crores of debt refinancing is planned to lower finance costs.
The quantified earnings path is visible: with SteriPort Line 3 at peak utilization and the SVP facility ramping, FY28 revenue of INR425 crores and EBITDA of INR116 crores are achievable, supported by operating leverage and solar savings. This requires SteriPort Line 3 to achieve 95-100% utilization within 12 months, SVP to clear regulatory approvals in advanced markets, and working capital days to stay manageable (around 141 days due to mandatory quarantine). The most critical watchpoint is the SteriPort Line 3 ramp-up; any failure to reach near full utilization by mid-2027 would compress the FY28 revenue and margin targets. Polymer price volatility, including a 70-80% spike earlier in 2026, could temporarily pressure margins despite price hikes. The tension between higher gross margins and lower PAT due to depreciation and interest is transient, as depreciation adds only INR6 crores annually and interest costs are expected to fall to INR18-19 crores by FY28, allowing PAT to grow faster than revenue.
companyname: AMANTA HEALTHCARE LIMITED ticker: AMANTA sector: Pharmaceuticals / Sterile Liquids (Large Volume and Small Volume Parenterals) Amanta Healthcare makes sterile liquids for hospitals: IV fluids as large volume parenterals (LVP) and a range of smaller injectable, irrigation, ophthalmic and respiratory products as small volume parenterals (SVP). It incorporated in 1994, is headquartered in Ahmedabad with its factory at Hariyala in Kheda district, Gujarat, and listed through its maiden ...
Read the full report →capex, margin expansion, new product segment, debt reduction
FY27 revenue growth guided at 22-25% driven by new capacity ramp-up; EBITDA margin expansion to 25-27% from SteriPort expansion
Guidance upgradedGet valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Amanta Healthcare Ltd and 4,900+ companies.
5-day free pass. No card required.